Publicacions en què col·labora amb Juan Cabezas Herrera (33)

2023

  1. Targeting protein methylation in pancreatic cancer cells results in KRAS signaling imbalance and inhibition of autophagy

    Cell Death and Disease, Vol. 14, Núm. 11

2021

  1. Acriflavine, a potent inhibitor of HIF-1α, disturbs glucose metabolism and suppresses ATF4-protective pathways in melanoma under non-hypoxic conditions

    Cancers, Vol. 13, Núm. 1, pp. 1-17

  2. MITF induces escape from innate immunity in melanoma

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

2020

  1. PRMT1-dependent methylation of BRCA1 contributes to the epigenetic defense of breast cancer cells against ionizing radiation

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Mitotic rate as an important prognostic factor in cutaneous malignant melanoma

    Clinical and Translational Oncology, Vol. 21, Núm. 10, pp. 1348-1356

  2. Prognostic value of the Breslow:diameter ratio in cutaneous melanoma

    Journal of the American Academy of Dermatology, Vol. 80, Núm. 3, pp. 806-808

2016

  1. Targeting the epigenetics of the DNA damage response in breast cancer

    Cell Death and Disease, Vol. 7

  2. Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis

    Oncogene, Vol. 35, Núm. 47, pp. 6143-6152

2015

  1. Dysregulated cholinergic network as a novel biomarker of poor prognostic in patients with head and neck squamous cell carcinoma

    BMC Cancer, Vol. 15, Núm. 1

  2. Targeting the epigenetic machinery of cancer cells

    Oncogene, Vol. 34, Núm. 2, pp. 135-143

  3. Unbalanced acetylcholinesterase activity in larynx squamous cell carcinoma

    International Immunopharmacology, Vol. 29, Núm. 1, pp. 81-86

2013

  1. Directed Phenotype Switching as an Effective Antimelanoma Strategy

    Cancer Cell, Vol. 24, Núm. 1, pp. 105-119

  2. Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma

    Neoplasia (United States), Vol. 15, Núm. 7, pp. 826-839

2012

  1. Changes in the expression and structure of cholinesterases in excitable and non-excitable tissues of the merosin-deficient Lama2dy mouse, a model of congenital muscular dystrophy

    Cholinesterase: Production, Uses and Health Effects (Nova Science Publishers, Inc.), pp. 1-32

  2. Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance

    Experimental Cell Research, Vol. 318, Núm. 10, pp. 1146-1159

  3. Reactivation of the Tumour Suppressor RASSF1A in Breast Cancer by Simultaneous Targeting of DNA and E2F1 Methylation

    PLoS ONE, Vol. 7, Núm. 12

2011

  1. Comparison of a Pair of Synthetic Tea-Catechin-Derived Epimers: Synthesis, Antifolate Activity, and Tyrosinase-Mediated Activation in Melanoma

    ChemMedChem, Vol. 6, Núm. 3, pp. 440-449

2010

  1. Analysis of cholinesterases in human prostate and sperm. Implications in cancer and fertility

    Chemico-Biological Interactions, Vol. 187, Núm. 1-3, pp. 432-435

  2. Mechanism of dihydrofolate reductase downregulation in melanoma by 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin

    Journal of Cellular Biochemistry, Vol. 110, Núm. 6, pp. 1399-1409

  3. Purification and kinetic properties of human recombinant dihydrofolate reductase produced in bombyx mori chrysalides

    Applied Biochemistry and Biotechnology, Vol. 162, Núm. 7, pp. 1834-1846